-
Je něco špatně v tomto záznamu ?
Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy
R. Mathieu, I. Lucca, T. Klatte, M. Babjuk, SF. Shariat,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- adjuvantní chemoradioterapie * škodlivé účinky MeSH
- časové faktory MeSH
- cystektomie škodlivé účinky metody MeSH
- invazivní růst nádoru MeSH
- karcinom patologie terapie MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- nádory močového měchýře patologie terapie MeSH
- rizikové faktory MeSH
- staging nádorů MeSH
- urotel * patologie MeSH
- výběr pacientů MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
PURPOSE OF REVIEW: Trimodal therapy (TMT) is considered the most effective bladder-sparing approach for muscle-invasive urothelial carcinoma of the bladder (MIBC) and an alternative to radical cystectomy. The purpose of this article was to review and summarize the current knowledge on the equivalence of TMT and radical cystectomy based on the recent literature. RECENT FINDINGS: TMT consists of a maximal transuretral resection of the bladder, followed by a concurrent radiotherapy and chemotherapy, limiting salvage radical cystectomy to nonresponder tumors or muscle-invasive recurrence. In large population studies, less than 6% of the patients with nonmetastatic MIBC receive a chemoradiation therapy and this rate is stable. A growing body of evidence exists that TMT provides good oncologic outcomes with low morbidity when compared with radical cystectomy. TMT requires, however, a close follow-up because of the high risk of local recurrence and salvage radical cystectomy in up to 30% of the patients. Salvage radical cystectomy can be performed with adequate results but does not offer the same opportunity of reconstruction and functional outcomes than primary radical cystectomy. SUMMARY: Although radical cystectomy is still the treatment of reference for most of the patients with localized MIBC, TMT represents a reasonable alternative in highly selected patients. Any firm conclusion on the equivalence or superiority of one treatment to the other is still limited by the lack of randomized controlled trials and the heterogeneity of the available literature. Future studies and multidisciplinary approach are mandatory to optimize the patient selection and regimen of TMT.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020609
- 003
- CZ-PrNML
- 005
- 20160725120606.0
- 007
- ta
- 008
- 160722s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MOU.0000000000000203 $2 doi
- 024 7_
- $a 10.1097/MOU.0000000000000203 $2 doi
- 035 __
- $a (PubMed)26125510
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mathieu, Romain $u aDepartment of Urology, Medical University Vienna, General Hospital, Vienna, Austria bDepartment of Urology, Rennes University Hospital, Rennes, France cDepartment of Urology, Centre hospitalier universitaire vaudois, Lausanne, Switzerland dDepartment of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Prague, Czech Republic eDepartment of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas fDepartment of Urology, Weill Cornell Medical College, New York, New York, USA.
- 245 10
- $a Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy / $c R. Mathieu, I. Lucca, T. Klatte, M. Babjuk, SF. Shariat,
- 520 9_
- $a PURPOSE OF REVIEW: Trimodal therapy (TMT) is considered the most effective bladder-sparing approach for muscle-invasive urothelial carcinoma of the bladder (MIBC) and an alternative to radical cystectomy. The purpose of this article was to review and summarize the current knowledge on the equivalence of TMT and radical cystectomy based on the recent literature. RECENT FINDINGS: TMT consists of a maximal transuretral resection of the bladder, followed by a concurrent radiotherapy and chemotherapy, limiting salvage radical cystectomy to nonresponder tumors or muscle-invasive recurrence. In large population studies, less than 6% of the patients with nonmetastatic MIBC receive a chemoradiation therapy and this rate is stable. A growing body of evidence exists that TMT provides good oncologic outcomes with low morbidity when compared with radical cystectomy. TMT requires, however, a close follow-up because of the high risk of local recurrence and salvage radical cystectomy in up to 30% of the patients. Salvage radical cystectomy can be performed with adequate results but does not offer the same opportunity of reconstruction and functional outcomes than primary radical cystectomy. SUMMARY: Although radical cystectomy is still the treatment of reference for most of the patients with localized MIBC, TMT represents a reasonable alternative in highly selected patients. Any firm conclusion on the equivalence or superiority of one treatment to the other is still limited by the lack of randomized controlled trials and the heterogeneity of the available literature. Future studies and multidisciplinary approach are mandatory to optimize the patient selection and regimen of TMT.
- 650 _2
- $a karcinom $x patologie $x terapie $7 D002277
- 650 12
- $a adjuvantní chemoradioterapie $x škodlivé účinky $7 D059186
- 650 _2
- $a cystektomie $x škodlivé účinky $x metody $7 D015653
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a invazivní růst nádoru $7 D009361
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a výběr pacientů $7 D018579
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a nádory močového měchýře $x patologie $x terapie $7 D001749
- 650 12
- $a urotel $x patologie $7 D019459
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Lucca, Ilaria
- 700 1_
- $a Klatte, Tobias
- 700 1_
- $a Babjuk, Marko
- 700 1_
- $a Shariat, Shahrokh F
- 773 0_
- $w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 25, č. 5 (2015), s. 476-82
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26125510 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160725120824 $b ABA008
- 999 __
- $a ok $b bmc $g 1155279 $s 945137
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 25 $c 5 $d 476-82 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
- LZP __
- $a Pubmed-20160722